Redfin Corporation Announces Proposed Public Offerings of

New Post Public Reply Private Reply Replies (0) Message Board
News Desk 2018
41
Redfin Corporation Announces Proposed Public Offerings of Common Stock and Convertible Senior Notes

SEATTLE, July 16, 2018 (GLOBE NEWSWIRE) -- Redfin Corporation (NASDAQ: RDFN ), the technology-powered residential real estate brokerage, announced today that it intends to commence concurrent underwritten public offerings of 3.5 million shares of common stock and $125 million aggregate principal amount of convertible senior notes due 2023.  Neither offering is contingent on the completion of the other offering.

Redfin also intends to grant the underwriters of the common stock offering a 30-day option to purchase up to an additional 525,000 shares and the underwriters of the notes offering a 30-day option to purchase up to an additional $18.75 million aggregate principal amount of notes, solely to cover over-allotments.

Redfin intends to use the net proceeds from the offerings for working capital and other general corporate purposes, which may include technology development and marketing activities, general and administrative expenses and capital expenditures. Additionally, Redfin may choose to use a portion of the net proceeds to invest in or acquire third-party businesses, products, services, technologies or other assets. However, Redfin has no definitive agreements or preliminary plans with respect to any such acquisitions or investments at this time.

The notes will be senior, unsecured obligations of Redfin, and interest will be payable semi-annually in arrears. The notes will mature on July 15, 2023 unless earlier repurchased, redeemed or converted. Prior to April 15, 2023, the notes will be convertible at the option of holders during certain periods, upon satisfaction of certain conditions. Thereafter, the notes will be convertible at any time until the close of business on the second scheduled trading day immediately preceding the maturity date. Redfin may redeem for cash all or any portion of the notes, at its option, on or after July 20, 2021 upon satisfaction of certain conditions. Redfin will settle conversions of the notes by paying or delivering, as the case may be, cash, shares of its common stock, or a combination of cash and shares of its common stock, at its election. The interest rate, conversion rate, and other terms of the Notes will be determined at the time of pricing of the notes offering.

Goldman Sachs & Co. LLC is acting as lead book-running manager for the common stock offering and the notes offering. BofA Merrill Lynch and RBC Capital Markets are acting as bookrunners for the common stock offering and the notes offering, and Allen & Company LLC is acting as bookrunner for the common stock offering. Oppenheimer & Co. is acting as co-manager for the common stock offering.

Each offering is being made only by means of a prospectus. Copies of the preliminary prospectus related to each offering, when available, may be obtained from Goldman Sachs & Co. LLC, Attention: Prospectus Department, 200 West Street, New York, New York 10282, or by telephone at (866) 471-2526 or by email at prospectus-ny@ny.email.gs.com.

A registration statement relating to these securities has been filed with the Securities and Exchange Commission (“SEC”) but has not yet become effective. These securities may not be sold, nor may offers to buy be accepted, prior to the time the registration statement becomes effective. This press release does not constitute an offer to sell or a solicitation of an offer to, nor shall there be any sale of these securities in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction.

Forward-Looking Statements

This press release contains certain forward-looking statements within the meaning of federal securities laws, including statements regarding the timing, including consummation, of the proposed offerings, the anticipated size of the common stock offering, the anticipated dollar amount of the notes offering, the expected use of the net proceeds from the proposed offerings, and the terms of the notes. We believe our expectations related to these forward-looking statements are reasonable, but actual results may turn out to be materially different than our expectations due to certain risks and uncertainties. These risks include, among other things: (i) unfavorable market reactions to our anticipated expansion of Redfin Now and our estimated preliminary results for the three months ended June 30, 2018, each as described in the prospectus for each offering, (ii) a downturn in the real estate industry, (iii) changes to our competitive environment, (iv) prevailing market conditions and (v) the impact of general economic, industry or political conditions in the United States or internationally. Additional risks and uncertainties that could cause the forward-looking statements in this press release to materially differ from actual results are included under the caption “Risk Factors” in our Annual Report on Form 10-K for the year ended December 31, 2017, as supplemented by our Quarterly Report on Form 10-Q for the three months ended March 31, 2018, both of which are available on the SEC website at www.sec.gov. Risks to purchasers of the common stock and the notes are described under the caption “Risk Factors” in the prospectus relating to the applicable offering.  All forward-looking statements reflect our beliefs and assumptions only as of the date of this press release. We undertake no obligation to update forward-looking statements to reflect future events or circumstances.

Redfin-F

Contacts

Investor Relations Elena Perron, 206-576-8610 ir@redfin.com

Public Relations Jani Strand or Rachel Musiker, 206-588-6863 press@redfin.com

Scroll down for more posts ▼

Top 10 Most Recent News Articles

Top 5 Most Recently Viewed Articles

Zenas BioPharma Investors Urged to Join Class Action Lawsuit

Updated Category News Views 119

Overview of the Class Action Lawsuit Levi & Korsinsky, LLP is reaching out to investors in Zenas BioPharma, Inc. regarding a crucial class action lawsuit. This lawsuit may greatly impact those who have invested in Zenas BioPharma as it seeks to compensate individuals who have suffered losses due to alleged securities fraud. Understanding the Legal Landscape This class...

Continue Reading
Ayar Labs Raises $155 Million to Transform AI Infrastructure

Updated Category News Views 716

Ayar Labs Secures Significant Funding to Enhance AI Infrastructure Ayar Labs has recently secured $155 million in financing aimed at addressing the critical needs in AI infrastructure. With backing from prominent investors such as AMD Ventures, Intel Capital, and NVIDIA, alongside Advent Global Opportunities and Light Street Capital, this investment elevates the total...

Continue Reading
Transforming the Non-Profit Sector: The Impact Collaborative

Updated Category News Views 159

Impact Collaborative Launches to Transform the Non-Profit Sector Today marks a significant milestone with the launch of the Impact Collaborative (IC), a pioneering initiative aimed at revolutionizing the support provided to under-resourced communities. This innovative approach seeks to disrupt generational poverty while offering much-needed access to mental health and...

Continue Reading
Synovus Financial Corp Declares Quarterly Dividends for Investors

Updated Category News Views 128

Synovus Financial Corp Declares Quarterly Dividends Synovus Financial Corp. (NYSE: SNV) has recently revealed the details of its latest quarterly dividends. The board of directors has approved significant payouts to its shareholders, reinforcing the company’s ongoing commitment to deliver value to its investors. Details of the Declared Dividends The following dividends...

Continue Reading
Walnut Hill Medical Enhances Patient Access Through FDA TAP Program

Updated Category News Views 171

Walnut Hill Medical Partners with FDA in TAP Program Walnut Hill Medical, a prominent healthcare consultancy known for its market access and reimbursement strategies, has been chosen as an advisor to the FDA's Total Product Life Cycle Advisory Program (TAP). This initiative, which originated from the FDA's Center for Devices and Radiological Health (CDRH), aims to improve...

Continue Reading